| Metric | Current Period | Prior-Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥367.3B | ¥366.1B | +0.3% |
| Operating Income / Operating Profit | ¥27.5B | ¥18.7B | +47.2% |
| Ordinary Income | ¥29.7B | ¥20.3B | +46.2% |
| Net Income / Net Profit | ¥22.7B | ¥10.9B | +108.3% |
| ROE | 4.3% | 2.1% | - |
For the nine months ended February 2026 (cumulative Q3), revenue was ¥367.3B (YoY +¥1.2B, +0.3%) essentially flat, while improvement in gross margin and containment of SG&A drove Operating Income of ¥27.5B (YoY +¥8.8B, +47.2%), Ordinary Income of ¥29.7B (YoY +¥9.4B, +46.2%), and Net Income attributable to owners of the parent of ¥22.7B (YoY +¥11.8B, +108.3%), delivering substantial profit growth. Gross profit margin improved to 19.4% (from 17.4%, +2.0pt) and SG&A ratio declined to 11.9% (from 12.3%, -0.4pt), expanding Operating Margin to 7.5% (from 4.8%, +2.7pt). Gain on sale of investment securities of ¥3.3B boosted pre-tax profit, lifting Net Profit Margin to 6.2% (from 3.0%).
Revenue grew marginally by +0.3% YoY, indicating limited top-line expansion. In the core Pharmaceuticals Business, increased production and sales activity is reflected in Accounts Payable up +30.8% (¥46.8B → ¥61.2B), indicating more active procurement. On profitability, Gross Margin improved to 19.4% (from 17.4%, +2.0pt), and Gross Profit increased by ¥7.4B to ¥71.2B due to a decline in cost ratio. SG&A decreased to ¥43.6B (from ¥45.1B, -¥1.4B, -3.2%), lowering the SG&A ratio to 11.9% and contributing to Operating Income expansion through cost control keeping SG&A growth below revenue growth. Non-operating income included equity-method investment gains of ¥0.8B, dividend income of ¥0.7B, and foreign exchange gains of ¥0.7B, supporting Ordinary Income and resulting in net non-operating contribution of +¥2.2B. A special gain of ¥3.3B from sale of investment securities was recorded, raising Profit Before Tax to ¥32.7B (from ¥24.1B, +35.7%), and Net Income rose sharply by +108.3% YoY. Corporate taxes were ¥10.0B (effective tax rate 30.6%), down from ¥13.2B. The contribution from special gains is temporary and should be distinguished from improvements on a recurring basis. In conclusion, the company posted revenue roughly flat and substantially higher profits (modest revenue growth, large profit growth) with margin improvement at the operating level as the primary driver.
Profitability: Operating Margin improved to 7.5% (from 4.8%, +2.7pt), Gross Margin to 19.4% (from 17.4%, +2.0pt), and SG&A ratio declined to 11.9% (from 12.3%, -0.4pt). Net Profit Margin rose to 6.2% (from 3.0%, +3.2pt), including the contribution from the ¥3.3B gain on sale of investment securities. ROE was 4.3%, still low but improved from the prior year due to higher net margins.
Cash quality: Days Sales Outstanding improved to 115 days (from 125 days), while Inventory Days worsened to 75 days (from 68 days), indicating inventory accumulation. Accounts Payable Days were 226 days, demonstrating use of payment terms. Cash Conversion Cycle (CCC) at 265 days remains extended, highlighting the need to improve working capital efficiency.
Investment efficiency: Total Asset Turnover was 0.490x, low, and a Fixed Asset Ratio of 48.9% indicates asset heaviness constraining efficiency.
Financial soundness: Equity Ratio was 69.8% (from 66.7%, +3.1pt), Current Ratio 249.6%, and Quick Ratio 210.1%, indicating ample liquidity. Interest-bearing debt (short-term borrowings + long-term borrowings + lease liabilities) is approximately ¥80B, and Interest Coverage was 28.7x, showing strong interest-service capacity. Long-term borrowings decreased -33.0% from ¥65.7B to ¥44.0B, reducing financial leverage.
Cash flow statement data is not disclosed; therefore, cash movements are analyzed from balance sheet trends. Cash and deposits were ¥18.7B (from ¥22.1B, -¥3.4B), suggesting prioritization of investment and financing uses over cash generation from operations. Trade receivables (notes and accounts receivable and electronic recorded monetary claims) were ¥116.1B (from ¥125.3B, -¥9.2B), indicating progress in collections. Inventories were ¥60.6B (from ¥68.4B, -¥7.8B), but work-in-process rose to ¥65.0B (from ¥63.3B, +¥1.7B), reflecting production cycle progression. Accounts Payable increased to ¥61.2B (from ¥46.8B, +¥14.4B), reflecting more active procurement and improved short-term liquidity management via payment terms. Long-term borrowings declined by ¥21.7B from ¥65.7B to ¥44.0B, compressing interest-bearing debt. Treasury stock increased from -¥7.5B to -¥12.9B (change -¥5.4B), indicating enhanced shareholder returns through buybacks. Intangible fixed assets rose to ¥10.8B (from ¥5.3B, +¥5.5B, +104.3%), suggesting expanded investment in technology/software. Overall, despite working capital constraints limiting cash generation from operations, the company has allocated funds toward debt reduction, shareholder returns, and strategic investments.
The large increase in Operating Income is mainly due to recurring factors: Gross Margin improvement of +2.0pt and SG&A ratio decline of -0.4pt, indicating improved quality of earnings at the operating level. Non-operating income of ¥3.4B equals 0.9% of revenue and consists largely of stable items such as dividend income ¥0.7B, foreign exchange gains ¥0.7B, and equity-method gains ¥0.8B, supporting high recurrence. However, at the pre-tax level, a special gain of ¥3.3B from sale of investment securities contributed, meaning approximately 14.6% of the ¥22.7B Net Income is attributable to a one-off. The divergence between Ordinary Income and Net Income is driven by tax burden (corporate taxes ¥10.0B, effective tax rate 30.6%) and special items, not structural issues. Comprehensive Income was ¥25.5B, ¥2.8B higher than Net Income of ¥22.7B, mainly due to valuation gains on securities of ¥2.7B, which increased shareholders’ equity. On an accrual basis, DSO 115 days, Inventory Days 75 days, and CCC 265 days reveal working capital lock-up and a time lag in converting profit to cash. For the next fiscal year, given the likely absence of recurring investment securities gains, it is necessary to assess underlying net income based on operating performance.
Progress against Full Year guidance as of Q3 cumulative: Revenue 72.0% of FY plan (standard 75% benchmark -3.0pt), Operating Income 83.4% (benchmark +8.4pt), Ordinary Income 85.0% (benchmark +10.0pt), indicating profit-side front-loading. Revenue is slightly behind, with ¥367.3B against FY plan of ¥510.0B (72.0% achieved), but Operating Income is ¥27.5B against FY plan ¥33.0B (83.4% achieved), and Ordinary Income is ¥29.7B against FY plan ¥35.0B (85.0% achieved), with margin improvement supporting better-than-planned profit progression. If improvements in Gross Margin and SG&A ratio continue, there is upside to FY Operating Income. However, the ¥3.3B special gain’s continuation into Q4 is uncertain, so FY Net Income achievement depends on progress at the Ordinary Income level. Monitor end-of-period revenue catch-up and seasonality in working capital (year-end inventory build) toward the fiscal year close.
An interim dividend of ¥20 per share was paid at the end of Q2. With issued shares of 30,096 thousand and treasury shares of 933 thousand deducted, the weighted average shares outstanding during the period were 29,625 thousand, yielding EPS of ¥76.53. Assuming the interim dividend of ¥20 per share as the full-year dividend, the Payout Ratio would be approximately 26.1%. The full-year dividend forecast is ¥20 per share, representing a conservative payout level. Treasury stock expanded from -¥7.5B to -¥12.9B (change -¥5.4B), confirming enhanced shareholder returns through buybacks. With Cash and Deposits of ¥18.7B and Retained Earnings of ¥377.0B, payment capacity is ample; Equity Ratio 69.8% and Current Ratio 249.6% support dividend sustainability. Given the relatively low payout of around 26%, there is room for future dividend increases, but decisions should consider potential erosion of special gains and progress in improving working capital efficiency.
Industry position (reference; company analysis): The company is classified in Pharmaceutical Manufacturing (pharma). Versus the industry median for 2025 Q3, Equity Ratio 69.8% exceeds the industry median 67.8%, indicating above-standard financial soundness. Operating Margin 7.5% substantially outperforms the industry median -218.2%, showing relatively strong profitability within the sector. Total Asset Turnover 0.49x exceeds the industry median 0.17x, indicating superior asset efficiency. DSO 115 days is better than the industry median 151 days, reflecting superior collection efficiency. Inventory Days 75 days is far below the industry median 282 days, indicating high inventory efficiency. Accounts Payable Days 226 days exceed the industry median 145 days, showing the use of payment terms for cash management. ROE 4.3% exceeds the industry median -35.8% but remains low in absolute terms, leaving room to improve capital efficiency. Revenue growth +0.3% outperforms the industry median -12.5%, indicating relative top-line stability. Overall, financial soundness and profitability are favorable within the industry, but capital efficiency in absolute terms is low, making growth and efficiency improvements key future evaluation points.
First, expansion of Operating Margin by +2.7pt despite flat revenue. Gross Margin improvement +2.0pt and SG&A ratio decrease -0.4pt resulted in Operating Income growth of +47.2% YoY, confirming a structural trend of margin improvement. Second, the ¥3.3B gain on sale of investment securities represents about 14.6% of Net Income; while Ordinary Income improvement is solidly operating-driven, the advance in Net Income includes one-off contributions, so assessing underlying Net Income assuming a reversal is important. Third, further strengthening of financial soundness: long-term borrowings -33.0% and compression of interest-bearing debt raised Equity Ratio to 69.8%, and treasury stock increased by -¥5.4B, enhancing shareholder returns. Current Ratio 249.6% and Interest Coverage 28.7x indicate strong financial resilience and flexibility in capital policy. Fourth, challenges in working capital efficiency: CCC 265 days and prolonged lock-up, with Inventory Days worsening, require monitoring as they constrain cash generation. Low ROE 4.3% and low ROIC are additional issues; sustainable gross margin improvements and working capital efficiency gains are levers to raise capital productivity.
This report is an AI-generated earnings analysis using XBRL financial statement data. It is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the company from public financial statements. Investment decisions are your responsibility; consult a professional advisor as needed.